Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 10/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12269279 | 0.78 | S1PR1 (0.68) | S1PR1S1PR3KCNH2FFAR1MAOB | |
| SCHEMBL1601244 | 0.75 | S1PR1 (0.52) | S1PR1S1PR3KCNH2FFAR1CYP26A1 | |
| SCHEMBL4566137 | 0.73 | S1PR1 (0.58) | S1PR1S1PR3KCNH2FFAR1MAOB | |
| SCHEMBL1601933 | 0.72 | S1PR1 (0.48) | S1PR1S1PR3KCNH2FFAR1MAOB | |
| SCHEMBL1603237 | 0.68 | S1PR1 (1.00) | S1PR1S1PR3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL5140103 | 0.68 | S1PR1 (0.42) | S1PR1S1PR3KCNH2FFAR1MAOB | |
| SCHEMBL1602329 | 0.67 | S1PR1 (0.53) | S1PR1S1PR3KCNH2FFAR1CYP26A1 | |
| SCHEMBL1602664 | 0.67 | S1PR1 (1.00) | S1PR1S1PR3KCNH2 | |
| SCHEMBL1601740 | 0.67 | S1PR1 (0.68) | S1PR1S1PR3KCNH2MAOBMAOA | |
| SCHEMBL1602267 | 0.67 | S1PR1 (0.81) | S1PR1S1PR3KCNH2FFAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364976-B1 | S1P receptor modulating compounds and use thereof | EPIX PHARM INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20110059945-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-7855193-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20080064677-A9 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2008-03-13 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20070173487-A1 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 5/4885KCNH2 2959/4885 |
| US-20080064677-A9 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 5/4885KCNH2 2959/4885 |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 5/4885KCNH2 2959/4885 |
| US-20110059945-A1 | S1P Receptor Modulating Compounds and Use Thereof | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 5/4885KCNH2 2959/4885 |
| US-20070173487-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 5/4885KCNH2 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.